Print Page | Sign In | Join Today
News & Press: Company News

ivWatch Teams with Terumo for Distribution

Friday, September 22, 2017  
Share |
ivWatch, a medical device company working for continuous IV infiltration and extravasation detection technology will now be distributed! Terumo Corporation, international medical device manufacturers and distributors, is the exclusive distributor of the ivWatch Model 400 and the ivWatch OEM board in Japan, and is a global licensing partner for Terumo products containing the ivWatch OEM board.

“We have partnered with ivWatch because they offer the most advanced technology to help minimize patient harm through the early detection of IV infiltration events,” said Tsuyoshi Tomita, group manager, General Hospital Products Group, General Hospital Company at Terumo Corporation. “We are confident that the ivWatch technology will help hospitals improve patient safety by reducing the harm caused by IV infiltration.”

IV therapy is the most common invasive hospital procedure worldwide. A recent study, conducted at a university hospital in Tokyo, Japan, found that catheters failed at a rate of 18.8 percent with 41.3 percent of those failures due to infiltration. Every failure of an IV results in a drug delivery error and carries the potential for reduced drug efficacy and physical harm.

“We are excited to partner with Terumo to help advance patient safety in Japan and on a global scale,” said Gary P. Warren, president and CEO of ivWatch, LLC. “Through the distribution of the ivWatch Model 400 and future integration of the ivWatch OEM board with Terumo products, Terumo will be able to help their customers deliver a higher level of patient care and reduced risks related to IV therapy. This partnership furthers our collective goal of ending the harm associated with IV infiltration and extravasation.”

IV infiltration and extravasation is a major problem as it can lead to serious medical complications and even amputation. The ivWatch Model 400 continuously monitors a patient’s peripheral IV for evidence of infiltrations and extravasations, which occur when medication or fluid leaks into the surrounding tissue. Early detection of those failures via ivWatch sensor technology helps to minimize injuries associated with this common complication of IV therapy.

ivWatch technology can be seamlessly integrated with patient monitoring systems, infusion pumps and other devices via the ivWatch OEM board. The agreement provides Terumo with exclusive rights to integrate ivWatch into existing and future Terumo products in Japan. In addition, Terumo can integrate ivWatch technology into products available globally.

Our Sponsors

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected